167 related articles for article (PubMed ID: 37889299)
1. Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [
Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):896-906. PubMed ID: 37889299
[TBL] [Abstract][Full Text] [Related]
2. Comparison of parametric imaging and SUV imaging with [
Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Zhou Y; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):568-580. PubMed ID: 37792025
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Determination of optimal
Wen J; Zhu Y; Li L; Liu J; Chen Y; Chen R
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2086-2095. PubMed ID: 34962583
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tracer kinetic models for
Smith NJ; Green MA; Bahler CD; Tann M; Territo W; Smith AM; Hutchins GD
EJNMMI Res; 2024 Jan; 14(1):6. PubMed ID: 38198060
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Tracer Kinetic Models for 68Ga-PSMA-11 PET in Intermediate Risk Primary Prostate Cancer Patients.
Smith NJ; Green MA; Bahler CD; Tann M; Territo W; Smith AM; Hutchins GD
Res Sq; 2023 Nov; ():. PubMed ID: 37961116
[TBL] [Abstract][Full Text] [Related]
8. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
9. Kinetic modeling and parametric imaging of
Yuan H; Zhang G; Sun T; Ren J; Zhang Q; Xiang Z; Liu E; Jiang L
Med Phys; 2024 Jan; 51(1):156-166. PubMed ID: 38043120
[TBL] [Abstract][Full Text] [Related]
10.
Sachpekidis C; Bäumer P; Kopka K; Hadaschik BA; Hohenfellner M; Kopp-Schneider A; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
[TBL] [Abstract][Full Text] [Related]
11. Early dynamic imaging in
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
[TBL] [Abstract][Full Text] [Related]
12. A prospective head-to-head comparison of [
Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
14. Kinetic modeling of
Ringheim A; Campos Neto GC; Anazodo U; Cui L; da Cunha ML; Vitor T; Martins KM; Miranda ACC; de Barboza MF; Fuscaldi LL; Lemos GC; Colombo Junior JR; Baroni RH
EJNMMI Res; 2020 Feb; 10(1):12. PubMed ID: 32140850
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.
Sachpekidis C; Kopka K; Eder M; Hadaschik BA; Freitag MT; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Nov; 41(11):e473-e479. PubMed ID: 27607173
[TBL] [Abstract][Full Text] [Related]
16. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
17. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
18. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
19. Tumor Sink Effect in
Gafita A; Wang H; Robertson A; Armstrong WR; Zaum R; Weber M; Yagubbayli F; Kratochwil C; Grogan TR; Nguyen K; Navarro F; Esfandiari R; Rauscher I; Menze B; Elashoff D; Delpassand ES; Herrmann K; Czernin J; Hofman MS; Calais J; Fendler WP; Eiber M
J Nucl Med; 2022 Feb; 63(2):226-232. PubMed ID: 34049987
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
